Activity of tricyclic nucleoside 5′-phosphate in model systems of human ovarian cancer
Autor: | Takashi Tsuruo, Karen R. Grotzinger, Thomas C. Hamilton, Wilma M. McKoy, Karen G. Louie, Robert F. Ozols, Brent C. Behrens, Robert C. Young |
---|---|
Rok vydání: | 1986 |
Předmět: |
Cell Survival
Transplantation Heterologous Drug Evaluation Preclinical Drug Resistance Antineoplastic Agents Pharmacology Cell Line Mice In vivo medicine Animals Humans Pharmacology (medical) Clonogenic assay Cytotoxicity IC50 Ovarian Neoplasms Mice Inbred BALB C Acenaphthenes business.industry Ribonucleotides medicine.disease In vitro Oncology Cell culture Drug Evaluation Female Ovarian cancer business Nucleoside Neoplasm Transplantation |
Zdroj: | Investigational New Drugs. 4:295-304 |
ISSN: | 1573-0646 0167-6997 |
DOI: | 10.1007/bf00173502 |
Popis: | Tricyclic nucleoside 5'-phosphate (TCN-P) was evaluated in two models of human ovarian cancer. TCN-P reduced both colony number and volume in clonogenic assays employing human ovarian cancer cell lines. TCN-P cytotoxicity depended on the concentration, exposure duration and cell line studied, but not on cell line plating efficiency or growth rate in soft agarose. Comparison of experimental IC50 concentrations for 1 hour or continuous TCN-P exposure with reported clinically relevant concentrations suggests that therapeutic TCN-P levels are more likely to be achieved by continuous infusions. Cell lines and sublines with resistance to several standard chemotherapeutic agents acquired both in vivo and in vitro were at most 2.6-fold cross-resistant to TCN-P with 1 hour drug exposure. Cross-resistance was not evident with continuous TCN-P exposure. Intermittent bolus TCN-P (100 mg/kg/d X 5) was ineffective in an in vivo xenograft model of human ovarian cancer. These data suggest that TCN-P is most likely to be clinically effective against ovarian cancer, and may be non-cross-resistant with several standard agents, if administered by continuous infusion. Preclinical evaluation of new agents, such as TCN-P, in these experimental models may provide information useful in subsequent clinical trials. |
Databáze: | OpenAIRE |
Externí odkaz: |